NEW YORK (GenomeWeb News) – Med BioGene on Thursday reported that it swung to a loss from a profit for the first half of 2012.

The Vancouver, British Columbia-based molecular diagnostics developer also said that it recorded no revenues for the six months ended June 30, compared to revenues of C$593,714 (US$597,795) for the first half of 2011, all of which were derived from licensing deals.

Its net loss for the first half of 2012 was C$223,418, or C$.00 per share, compared to a profit of C$215,034, or C$.00 per share, for the first half of 2011.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.